This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

U.S. Distributor Appointed For Bioniche's Immunocidin(TM) Canine Oncology Therapy

- Vedco, Inc. of St. Joseph, Missouri selected as U.S. distributor -

BELLEVILLE, ON, Nov. 21, 2012 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that it has appointed an exclusive U.S. distributor for its Immunocidin TM canine oncology therapy: St. Joseph, Missouri-based Vedco, Inc. Immunocidin TM was launched at the annual U.S. Veterinary Cancer Society conference in October of this year.

Immunocidin TM is based on the Company's proprietary mycobacterial cell wall technology, the same platform from which its Phase III product for human bladder cancer ( Urocidin TM ) was derived. Immunocidin TM is indicated as an immunotherapy for the intratumoral treatment of mixed mammary tumor and mammary adenocarcinoma in dogs. The product has received regulatory approval in Canada and the U.S. and is expected to be launched in Canada in January, 2013.

Vedco will begin immediate distribution of Immunocidin TM to veterinarians via its group of member distributors which includes Butler Schein Animal Health, Merritt Veterinary Supply, Miller Veterinary Supply, MWI Veterinary Supply, Penn Veterinary Supply and Webster Veterinary Supply.

"We are pleased to have Vedco, Inc. as our U.S. distribution partner for this product," said Mr. Andrew Grant, President, Bioniche Animal Health (global). "Vedco is known for its broad and respected distribution network, comprising more than 1,000 sales representatives throughout the U.S."

Unlike commonly used canine oncology therapies, such as chemotherapy, Immunocidin TM does not require special handling and can be used by veterinarians in their own clinics, either alone or in combination with other therapies.

About Canine Cancer

Canine cancer is the leading disease-related cause of death in dogs, with approximately one in four dying of cancer.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs